161 results on '"Bhor, Menaka"'
Search Results
2. 1145. Meningococcal B Immunization for Adolescents in the Presence of Added Gonorrhea Protection: A Public Health Impact Modelling Study in the United States
3. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer
4. Economic Modeling of the Combined Effects of HIV-Disease,Cholesterol and Lipoatrophy Based on ACTG 5142 Trial Data
5. Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States
6. Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
7. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study
8. A systematic review to assess the burden of ischemic priapism in patients with sickle cell disease
9. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting
10. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices
11. Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease
12. Everolimus vs. Temsirolimus for Advanced Renal Cell Carcinoma: Use and Use of Resources in the US Oncology Network
13. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports
14. The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US
15. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review
16. Development and validation of a scale to assess attitudes of health care administrators toward the use of e-mail communication between patients and physicians
17. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study
18. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers
19. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study
20. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study
21. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists
22. A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease
23. How Does Sickle Cell Disease Severity Affect Patient Collection of Disability Insurance and Income: An Analysis of US Survey Data
24. Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective
25. Relationship between Vaso-Occlusive Crisis and Quality of Life: An Analysis of Patients with Sickle Cell Disease in the United States
26. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study
27. Sickle cell disease complications: Prevalence and resource utilization
28. Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study
29. Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data
30. Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
31. Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
32. Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
33. Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
34. Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat
35. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists
36. Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings
37. Comparison of treatment characteristics between patients diagnosed with immune thrombocytopenia (ITP) and treated with thrombopoietin receptor agonists (TPO-RA).
38. Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients
39. Sequencing in metastatic castrate-resistant prostate cancer with enzalutamide in a post-chemotherapy setting.
40. Comparison of real-world acute care interventions (ACI) in patients (pts) with advanced non-small cell lung cancer (adv NSCLC) treated with chemotherapy versus targeted therapies.
41. Predictors of Increase in Emergency Room (ER) Visits and Hospitalizations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Chemotherapy
42. Predictors of Emergency Room (ER) Visits and Hospitalizations in Patients with Mantle Cell Lymphoma (MCL) Treated with Chemotherapy
43. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices
44. Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia
45. Electronic prescribing: Problem or panacea?
46. An analysis of early molecular testing, time to treatment initiation, and medical resource use in metastatic NSCLC.
47. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received (neo)adjuvant chemotherapy in community oncology practices.
48. Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).
49. A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting
50. Association Between Treatment Adherence and Response Among Patients With Chronic Myeloid Leukemia (CML) Receiving First-Line TKIs In The Community Setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.